Over the last twenty years, increasing numbers of critically ill, mechanically ventilated patients who develop acute profound muscle weakness have been described. These acute weakness syndromes have not been well understood and they have been given many names including: acute steroid myopathy, acute quadriplegic myopathy, the floppy person syndrome, critical illness polyneuropathy, critical illness polyneuromyopathy, and prolonged neurogenic weakness. Many of these "syndromes" either overlap or represent the same disease process in different patients. Many have been incompletely diagnosed.
In critically ill mechanically ventilated patients, acute weakness syndromes sometimes including quadriplegia have been increasingly reported. These syndromes have been associated with failure to wean from mechanical ventilation, with prolonged stays in intensive care and in hospital, with increased need for prolonged rehabilitation and with increased patient morbidity and mortality [1] [2] [3] . Furthermore, recent prospective clinical studies report that the incidence of peripheral nerve, neuromuscular junction (NMJ) and muscle abnormalities in critically ill patients is very high, and much greater than previously suspected. In some studies, these abnormalities have been reported in up to 96% of patients who have been mechanically ventilated for more than seven days 2, 4 . Weakness syndromes are associated with disuse atrophy, myopathy, NMJ abnormalities, or neuropathy, and there are some with a mixed aetiology. The severity of weakness is highly variable, but includes quadriplegia and a prolonged recovery period of between six and eighteen months in 1.5% of intubated critically ill patients 5 . In occasional patients, quadriplegia does not resolve 5 . The complex clinical and histological abnormalities are often incompletely reported and have no widely accepted classification system. Aetiological factors, particularly the importance of neuromuscular blocking and corticosteroid drugs, have not been well understood. Basic distinctions in many of these patients, like the difference between myopathy and neuropathy, have often not been clearly made.
The first of the new acute weakness syndromes in critically ill patients was described in 1974 when ten children with acute asthma who developed a motor neuropathy were reported 6 . Following this there have been many other reports of acute myopathy and other quadraplegic syndromes in critically ill patients with acute asthma 3, [7] [8] [9] . In 1983, acute motor neuropathy was described in patients with sepsis and multiple organ dysfunction syndrome (MODS) and named "critical illness polyneuropathy" (CIP) 10 . In 1985, denervation was suggested as the cause of weakness in critically ill patients receiving aminoglycosides and neuromuscular blocking drugs (NMBAs) 11 . Many other patients with severe weakness associated with NMBAs have also been reported. In 1987, disuse atrophy was suggested as the aetiology of quadriparesis in a patient with acute asthma after prolonged use of NMBAs, corticosteroids and aminoglycosides. This patient had no evidence of neuropathy, myopathy or of neuromuscular block 12 . In 1990, a myasthenic syndrome compatible with a neuromuscular junction abnormality was reported following the use of NMBAs 13 , and in 1991 "necrotizing myopathy of intensive care" was described 14, 15 .
In 1992 and 1993, two prospective clinical studies of weakness syndromes in critically ill patients were published. Kupfer 16 described ten patients (eight with acute severe asthma) who required prolonged vecuronium infusions for mechanical ventilation but who did not have MODS or sepsis. Seventy per cent of these patients developed a weakness syndrome with electromyographic evidence of polyneuropathy without myopathy. In these patients there was coincident use of corticosteroids in eight of ten patients, and muscle biopsies which are required to unequivocally exclude myopathy were not performed. In the same year Douglass 3 reported 25 patients with asthma who developed similar weakness and had similar risk factors, but concluded that the primary problem was myopathy. Coakley 2 then reported 23 patients with a variety of conditions who were resident for longer than seven days in intensive care. A wide range of histological and neurophysiological abnormalities were reported but neither corticosteroids, NMBAs, sepsis or MODS could be implicated. These studies indicate that clear differentiation between neuropathy and myopathy in critically ill patients cannot often be made without both electromyograhic studies and muscle biopsy, and also that on careful testing, abnormalities of both nerve and muscle are very widespread in critically ill patients.
Many of these entities have been described in patients with common aetiological factors and diagnoses have often been made following incomplete investigations. In recent years EMG testing has become more common, but under some circumstances can mislead the diagnosis if interpreted without independent assessment of muscle function 17 . Blood CPK measurements and muscle biopsies are also needed to fully characterize some of the neuromuscular diseases and these have only been done in selected patients and in more recent years. Taking into account these difficulties, this review assesses the validity of each proposed syndrome and constructs a simplified classification (Table 1) .
Although four major syndrome groups exist (Table  1) , the majority of critically ill patients at risk of developing these acute weakness syndromes fall into three clinical settings ( Figure 1 ). First are patients who are receiving mechanical ventilation and drugs including corticosteroids, NMBAs, beta 2 agonists, methylxanthines and/or aminoglycosides. These patients most commonly have acute severe asthma but may instead have chronic obstructive airways disease or be heart/lung transplant recipients. Although they usually have myopathy, neuropathy has also been reported 16, 18 . Second are patients with kidney and liver dysfunction who have received prolonged infusions of NMBAs. Some of these patients also have received aminoglycosides 19, 20 , and have prolonged neuromuscular blockade. Third are patients with sepsis or MODS who have not received corticosteroids or NMBAs but who nevertheless have required prolonged intensive care admissions. These patients predominantly have neuropathy. CLINICAL WEAKNESS SYNDROMES 1. MYOPATHY
Disuse atrophy
All critically ill patients have high levels of catabolism as a normal response to critical illness, and when catabolism is combined with immobility for more than six days, disuse atrophy can develop. The 503 ACUTE WEAKNESS SYNDROME IN CRITICALLY ILL PATIENTS Anaesthesia and Intensive Care, Vol. 25, No. 5, October 1997 degree of atrophy depends on age, prior health status and severity of illness. Cytokines associated with infection, particularly interleukin-1, increase myoblast protein degradation, and the presence of infection may hasten this process. When NMBAs have also been used, the severity of muscle atrophy is likely to be increased because the disuse factor is more complete. In critically ill patients, disuse atrophy should be considered not as an independent entity, but as a common baseline condition upon which other processes (myopathy, neuropathy) will often be superimposed.
Muscle biopsy may be one of the ways to distinguish disuse atrophy from other processes. On biopsy, muscle atrophy has a uniform reduction in fibre size without the patchy necrosis, myosinolysis and vacuolization which is seen in myopathy. A problem with interpretation of muscle biopsies in patients with myopathy is that the reported changes in type IIb muscle fibres are nonspecific, and are also seen in muscles with disuse atrophy 21, 22 . However in most cases, the distinction between atrophy and true myopathy is not difficult.
Acute Necrotizing Myopathy
Acute necrotizing myopathy was first described in 1977, and between 1977 and 1988 only ten cases (most in women) had been reported in the English literature 7 . Over the 15 years from 1977, numerous alternative names were applied to this syndrome, including "acute hydrocortisone myopathy", "acute steroid myopathy", "floppy person syndrome" and "acute myopathic syndrome" 23 . More recently the most commonly used terms have been "myopathy of asthma" and "acute myopathy of intensive care (AMIC)" 24 . In 1992 an incidence of acute weakness in 36% of critically ill patients with acute severe asthma who required mechanical ventilation was reported 3 , suggesting that the incidence was much higher than previously suspected. The clinical findings were diffuse weakness and flaccid paralysis of all limbs, varying in severity from mild weakness to complete quadriplegia. Facial, ocular and respiratory muscles were sometimes involved 25, 26 . In more severe cases, deep tendon reflexes were reduced but intact when weakness was minimal, and were absent when weakness was severe 27 . No sensory deficits were present. Fifty per cent of the patients with probable muscle injury (elevated blood CPK concentrations) were asymptomatic. Blood concentrations of CPK were increased in 76% of patients 3 , although the increases were often small. Nerve conduction studies usually reported normal velocities and low motor amplitudes. Electromyographic studies have been characteristically myopathic but recruitment has often been poorly reported. Co-existing obtundation may confound an adequate EMG assessment. Some muscle biopsies report type II atrophy only and others report rhabdomyolysis with muscle cell vacuolization. Other changes on muscle biopsy which have been noted are considered consistent with chronic steroid myopathy 3, 28, 29 . When an EEG has been performed, generalized slow wave activity has usually been reported 25 .
In patients with acute severe asthma, acute myopathy usually becomes clinically evident during the weaning phase of mechanical ventilation. The syndrome was first thought to be solely due to highdose hydrocortisone 7, 9, 30 , then to high doses of corticosteroids of all types after being described in patients receiving methylprednisolone and dexamethasone, and finally to a combination of high dose corticosteroids and prolonged use of NMBAs 3, 31 .
Vecuronium has been the NMBA most commonly associated with myopathy and patients receiving longterm vecuronium infusions have been variously described as having "acute quadriplegic myopathy (AQM)", "myopathy with thick filament loss" or "prolonged reversible quadriparesis" 27, 32, 33 . However other NMBAs including pancuronium 3 , atracurium 34 and doxacurium 35 have also been associated with this syndrome. Therefore it seems likely that the syndrome is associated with muscle paralysis in general rather than with a particular NMBA. Importantly, there are also some cases where vecuronium and its metabolites have been responsible for prolonged paralysis without neuropathy or myopathy being present 36 .
Aminoglycosides potentiate neuromuscular blockade, and may cause prolonged weakness without muscle injury 37 , but prolongation of muscle inactivity has also been reported as a contributor to muscle injury. Aminoglycosides have also been implicated aetiologically in the myopathic quadraplegic syndrome termed "the floppy person syndrome" reported in patients with acute severe asthma receiving aminoglycosides together with steroids and NMBAs 38 , and also in other patients with myopathy receiving aminoglycosides and NMBAs alone 31, 39 . These reports are all likely to be of the same syndrome, but because the histologic features were minimally described in some, this is uncertain. Finally, there are also several case reports of patients with asthma and prolonged respiratory failure who had received aminoglycosides together with corticosteroids, and NMBAs. (See Table 1 .) It is likely that some of these patients had prolonged neuromuscular blockade due to aminoglycosides, and that others had myopathy predominately associated with NMBAs and corticosteroids.
Acute necrotizing myopathy of intensive care (ANM-IC) has been described as a syndrome distinct from asthma myopathy but both are likely to be different manifestations of the same syndrome. In 1991, Helliwell described necrotizing myopathy and weakness in 15 of 31 critically ill patients 14 . Ramsay 15 later described an intensive care acquired acute quadriplegic syndrome due to necrotizing myopathy in critically ill patients who had been receiving large cumulative doses of NMBAs and steroids. In a following report, Zochodne 40 questioned the importance of corticosteroids because two of their seven most recent patients had not received corticosteroids. Finally, Giostra 5 described seven critically ill patients with all the same characteristics.
In these patients the clinical picture was described as one of severe weakness through to quadriplegia which became evident during weaning from mechanical ventilation and which was often accompanied by areflexia and ophthalmoplegia. Increased blood creatinine phosphokinase (CPK) concentrations were correlated with the severity of the muscle necrosis and reached levels higher than 10,000 U/ml 15 . Acute renal failure due to myoglobinuria has been reported. Electrophysiological studies have been reported as normal and as mildly decreased conduction velocities with low amplitude motor responses, or as neuropathy 40 . In the first week of clinical weakness, 36% of serial muscle biopsies report necrosis. In the second week, atrophy has been noted in 50% of biopsies and necrosis in a similar proportion. During the third week, atrophy and necrosis are both reported in 50% of the samples, and only 16% are normal. Rapidly progressive necrosis destroying 70% of the muscle fibres in only six days has been reported 14 . The frequency of muscle necrosis has been related to the severity of illness, being present in 70% of patients who had four or more organs in failure 14 . Mortality of these patients has been reported as between 70 and 80%, and the prognosis is worse in patients with bone marrow dysfunction or acute renal failure.
Recovery in the presence of steroid therapy has been noted 9 , as has relapse on re-challenge 3 . Prognosis is often good and recovery is reported to take between one and six months 41 . Mortality has been reported to be 11-12% 3 , but recovery is in large part influenced by the underlying disease process and its co-existing morbidity. For example in the authors' experience, patients with severe asthma and myopathy tend to have more favourable outcomes than patients with heart/lung transplants which are complicated by acute necrotizing myopathy.
To summarize, acute necrotizing myopathy occurs in critically ill patients who have muscle inactivity or paralysis in the presence of corticosteroids. These and other contributing factors will be discussed in more detail later.
NEUROMUSCULAR JUNCTION ABNORMALITIES 2.1 Myasthenic Syndrome
Benzing 13 first described a two-year-old child with asthma and pneumonia who developed severe quadriparesis lasting six weeks due to an acute terminal motor axonopathy causing presynaptic conduction blockade. This patient had received steroidal NMBAs infused for seven days, inhaled betaagonists, corticosteroids and aminoglycosides. The child was flaccid, had absent deep tendon reflexes, no facial or extraocular muscle weakness, and no sensory loss. CSF and blood CPK were normal. Electrophysiological studies suggested a presynaptic neuromuscular junction (NMJ) disorder similar to that observed in myasthenic patients, with low amplitude motor nerve responses, and with incremental responses to high frequency stimulation and low amplitudes (myopathic changes) in the needle EMG. However muscle biopsy reported targetoid muscle fibre atrophy due to partial denervation with no evidence of re-inervation. EEG demonstrated mild, diffuse generalized slowing. In this patient there was complete recovery.
Coakley 42 reported three mechanically ventilated adults with either asthma or COAD who were receiving corticosteroids, NMBAs, antibiotics and inhaled beta-agonists who had similar clinical presentations and findings on EMG. In these patients, damage to the NMJ by NMBAs was considered likely.
Prolonged Neuromuscular Blockade
Segredo 36 first described prolonged paralysis (from six hours to seven days) following the administration of vecuronium. Prolonged neuromuscular blockade was considered likely to be due to the longacting, active vecuronium metabolite 3-desacetylvecuronium 43, 44 . Multivariate analysis identified the associated features as renal failure, metabolic acidosis, elevated plasma magnesium levels and female sex. Some of these factors may have delayed clearance of the long-acting active metabolite.
NEUROPATHY

Critical Illness Polyneuropathy (CIP)
Critical illness polyneuromyopathy is an acute, diffuse, mainly motor neuropathy due to axonal dysfunction described in critically ill patients with sepsis or multiple organ dysfunction syndrome 41 . It has been recognized since 1983 10, 45 . A very high incidence (up to 75%) has been reported in patients with sepsis and MODS 4 but only 50% of these patients were symptomatic. It has also been recently described in children 46 . The clinical picture was severe quadriplegia sometimes affecting facial muscles and cranial nerves, which may complicate the weaning of a patient with sepsis or MODS. Deep tendon reflexes were absent. Blood CPK concentrations were usually normal. Many patients had encephalopathy, with nonspecific EEG abnormalities of variable severity 45 . CSF was normal. Nerve conduction was normal with the first sign of abnormality on EMG being a reduction in the muscle compound action potential. Between the first and third week of illness, fibrillation potentials and positive sharp waves have characteristically appeared 47 . Another important finding was that motor unit potentials were reduced and polyphasic raising the possibility of an associated myopathy 48, 49 . Nerve biopsies have shown severe axonal degeneration affecting distal segments, and muscle biopsies 43, 50 have suggested denervation atrophy. CIP may be very difficult to distinguish from Guillain-Barré syndrome ( Table 2 ). The prognosis of this patient group with CIP is poor, with an overall patient mortality varying from 47% to 73% 50 . Clearly the prognosis is in large part dependent upon the severity of the underlying MODS. In the survivors, the prognosis of the CIP is good. Although recovery may take weeks to months and require rehabititation in some, full or near full recovery is common.
Finally, five patients have been described who developed a quadriplegic syndrome resembling CIP after an episode of acute respiratory failure 18 . This syndrome has been called "acute respiratory failure neuropathy", and is considered to be a variant of CIP, with similar aetiology but a different presentation. Patients had asthma, COAD, or ARDS. Most were receiving corticosteroids, NMBAs and antibiotics. Although these patients had risk factors for myopathy, blood CPK measurements and muscle biopsies were not done. The authors were confident that the EMG recruitment patterns were neurogenic but it is possible instead that these patients either had acute necrotizing myopathy (with misleading EMG findings) or a combined picture involving both syndromes 17 . Electrophysiological studies were compatible with peripheral demyelination and axonopathy. Needle electromyography did not show evidence of denervation. Blood CPK measurements and muscle biopsies were not done but the case was described as a variant of GBS. Apart from an EMG suggesting demyelination, this case was indistinguishable from acute necrotizing myopathy. Plasmapheresis, and hyperimmune globulin have been proposed as treatment. This patient had prolonged dependence on mechanical ventilation and a recovery period of over two months 52 . Undoubtedly there are also some patients who have been admitted to intensive care with other presentations (e.g. trauma) who may have had unrecognized acute Guillain-Barré Syndrome at presentation (muscle weakness may have predisposed to trauma), and there may be others who have developed Guillain-Barré Syndrome in response to the illness precipitating admission to intensive care. However in view of the recent clarification and recognition of both CIP and acute necrotizing myopathy, the previously recognized association between GBS and trauma should be critically reappraised. Furthermore, it seems likely that because mild GBS causes immobility, it may thereby predispose with other factors to the development of necrotizing myopathy. Again, in the absence of serial blood CPK measurements and a muscle biopsy, myopathy as cause or component of the GBS cannot be excluded.
Hopkins Syndrome (Poliomyelitis-Like Illness in Asthma)
Hopkins is an Australian paediatric neurologist who in 1974 first described ten children with asthma and an acute paralytic syndrome which appeared to be secondary to neurological damage to the anterior horn cells 6 . Axonal damage had not been excluded and the aetiology was unknown. A neurotropic virus similar to the poliomyelitis virus had been suggested as possible cause. Children reported in the first paper were immunized against poliomyelitis. The clinical manifestations, (flaccid paralysis of a single arm or leg, and fever), appeared about three days after an episode of acute asthma. CSF proteins were mildly elevated and occasionally pleocytosis was observed. Between 1974 and 1991, 22 cases were reported 53 . In these children, severe motor deficit never completely recovered, which suggests loss of anterior horn cells. Muscle biopsies showed group atrophy. The feature which most sets Hopkins Syndrome apart from acute necrotizing myopathy is the marked asymmetry of the clinical signs and the absence of necrosis on muscle biopsies. This feature strongly suggests that these syndromes are separate entities, not different manifestations of the same.
POLYNEUROMYOPATHY
Features of neuropathy and myopathy may coexist in some patients, and some authors have suggested that both CIP and acute necrotizing myopathy are mixed polyneuromyopathies. Hirano 32 reviewed 33 cases and identified 12% associated with neuropathy, and two with mixed abnormalities on EMG. Lacomis 29 reported a woman with acute asthma, who developed both acute myopathy and reversible neuropathy.
OpdeCoul 41 described polyneuromyopathy in a series of 22 critically ill patients. In some of these patients there were electromyographic changes of neuropathy, in others of myopathy, and others had both features. Muscle biopsies were performed in seven patients but blood CPK concentrations were not reported.
In mechanically ventilated patients with quadraplegia but without sensory defecit, electromyographic signs of axonal neuropathy and muscle fibre necrosis with high blood CPK concentrations have been described 40 . Coakley 2 also reported a series of patients with features of both neuropathy and myopathy, and patients with electrophysiological abnormalities always had associated abnormal histology on muscle biopsy. Four patients had histological and electrophysiological evidence of both neuropathy and myopathy. Helliwell 14 performed muscle biopsies on 31 critically ill patients and found 22 with histological changes that varied from denervation to necrosis.
It seems likely that the presence of either neuropathy or myopathy may provide an environment in which the other process is encouraged. Neuropathy for example may produce limb immobility which then predisposes to corticosteroid induced acute necrotizing myopathy. Likewise, the immobility of myopathy may predispose to CIP. Furthermore, both patient groups are likely also to have disuse atrophy which can be confused with myopathy, and both may develop muscle necrosis.
CONTROVERSIES
Aetiology of "Acute necrotizing myopathy" (myopathy of asthma; acute myopathy of intensive care)
Chronic corticosteroid administration is wellknown to cause myopathy in animals 28 and in humans 54 . Rouleau 55 reported loss of myosin in dener-507 ACUTE WEAKNESS SYNDROME IN CRITICALLY ILL PATIENTS vated rat muscle exposed to steroids for seven days. Afifi 28 reported that steroids caused fragmentation of contractile material in the muscle subsarcolemmal area of rabbit diaphragm by 12 hours after administration. By 48 hours there was progression, and precise analysis of the degenerative changes was possible. After four days the most severely affected fibres underwent phagocytosis and other fibres showed strong PAS reaction. Full recovery was observed four days after steroids had been ceased. In humans receiving chronic corticosteroids, the incidence of weakness was about 50% when patients with asthma received oral prednisone at doses greater than 40 mg per day 56 .
In recent years however, corticosteroids have also been clearly implicated aetiologically in acute myopathy. At first, high-dose hydrocortisone alone 7 and later, corticosteroids in general were implicated 57 . A receptor-based mechanism has been proposed 58 , which may explain the link between corticosteroids and NMBAs in this condition. There is a rise in the number of glucocorticoid receptors observed 24 hours following denervation which increases the sensitivity of the muscle to normal corticosteroid concentrations and induces negative nitrogen balance and muscle atrophy. Five days after denervation a 50% loss of basal and catecholamine-stimulated adenylate cyclase has been observed. The lack of beta-adrenergic responsiveness can be attributed to loss of muscle mass 58 .
Numerous case reports of weakness in patients with acute severe asthma receiving corticosteroids and NMBAs with and without aminoglycosides have been published. Relapse of muscle weakness and rise in blood CPK concentrations on rechallenge with steroids alone during the recovery phase of myopathy has also been reported 3 . Higher blood CPK concentrations and greater incidence of myopathy have been reported with higher doses of NMBAs like vecuronium which have a steroidal structure 3, 40 . The steroid-like structure of vecuronium has been suggested to be more myotoxic than chemically un-related NMBAs like atracurium, but most recent data suggest that this is not the case 34 . Progressively decreasing blood CPK concentrations have been observed after cessation of vecuronium. Both vecuronium and its metabolites, particularly 3-desacetyl-vecuronium have been implicated. Together these are held responsible for many cases of prolonged neuromuscular blockade in critically ill patients 16, 40 . The functional denervation that accompanies neuromuscular junction blockade appears to leave the muscle more sensitive to corticosteroid drugs.
Aminoglycosides may also have neuromuscular blocking side-effects. In 1970, Pittinger 20 reviewed 83 reports in which neomycin was implicated in muscle relaxation. Weakness has been reported with aminoglycosides in association with anaesthesia, with NMBAs and with renal failure. Animal studies demonstrate a dual effect of aminoglycosides at the NMJ. Aminoglycosides both inhibit prejunctional release of acetylcholine and also reduce postsynaptic sensitivity to the transmitter 19, 59 . These effects may be treated with intravenous calcium. Gentamicin also potentiates cholinergic dysfunction from hypermagnesemia 60 . Other antibiotics including polymixin B, oxytetracycline and clindamycin have also been associated with neuromuscular blockade 61 .
Intravenous beta-adrenergic drugs have also been used in almost all patients with asthma who develop muscle weakness, in part a reflection of the severity of asthma in these patients. Maguire 62 reported increased blood concentrations of CPK-MB in children receiving intravenous isoproterenol, suggesting myocardial injury. Kurland 63 reported a fatal case of focal myocardial necrosis in a young asthmatic receiving intravenous isoproterenol, aminophylline and subcutaneous adrenaline. Sykes 64 studied 13 patients with "brittle asthma" and reported that those who received subcutaneous terbutaline had elevated blood CPK concentrations and normal MB fractions. EMG performed in five patients supported a diagnosis of myopathy in two. Beta-adrenergic agonists 508 J. L. NATES, D. J. COOPER ET AL Anaesthesia and Intensive Care, Vol. 25, No. 5, October 1997 and theophylline have also been associated with rhabdomyolysis 65, 66 . Barret 67 reported two asthmatic patients with rhabdomyolysis but no weakness who had received steroids but no NMBAs. Betaadrenergic agonists predispose to the development of lactic acidosis (predominantly by increasing hepatic glycogenolysis) 68 and lactic acidosis is a frequent observation in patients who later are noted to have myopathy. However a causal link between myopathy and lactic acidosis has not been described and does not seem likely. Ramsay 15 recently reviewed a series of patients with necrotizing myopathy. "Priming" and "triggering" factors were concluded to be important. The "priming" factors were glucocorticoids and infection (either muscle or systemic), and the "triggering" factor was prolonged paralysis usually due to nondepolarizing NMBAs.
Aetiology of Critical Illness Polyneuropathy (CIP)
Bolton 1 suggested one mechanism whereby critical illness polyneuropathy might develop. First the sepsis syndrome is known to be associated with abnormalities in the microcirculation and increased capillary permeability. This may produce energy depletion of affected peripheral nerves causing distal axonal degeneration, typical of CIP. Following this, substances like NMBAs, their metabolites and antibiotics could enter the endoneurial space and further damage the axons. A similar mechanism might also apply to muscle.
Cytokines including Tumor Necrosis Factor (TNF-α), and an autotoxin in the MODS syndrome, have also been suggested in the pathophysiology of CIP 41, 69 . Verheul 70 however found TNFα and IL-6 not significantly elevated in patients with CIP compared to controls.
Hyperosmolality and hyperglycaemia were suggested as causes of CIP 71 when correction of metabolic abnormalities in affected patients was associated with total or partial disappearance of weakness over 48 hours. Witt 4 later found that increased blood glucose, decreased serum albumin and longer stays in intensive care were correlated with peripheral nerve dysfunction. Hyperglycaemia increases endovascular resistance, reduces nerve blood flow and causes endoneurial hypoxia. The fall in albumin could be a marker of increased microvascular permeability which theoretically causes endoneurial oedema, and further hypoxia.
Wilmshurst 72 reported two patients who developed CIP after severe hyperpyrexia and suggested that fever could be another possible aetiological factor. Body temperatures greater than 41 degrees Celsius are associated with denaturation of proteins, especially in the central nervous system where cells of the cerebellum and cerebral cortex may be damaged. Peripheral neuropathy has also been described after heat stroke 73 . However it is also possible (and indeed likely) that the cytokines responsible for temperature elevation are concomitantly involved directly in the pathogenesis of CIP.
Aetiological Role of Neuromuscular Blocking
Agents (NMBAs) Vecuronium and pancuronium have been frequently suggested as causes of prolonged paralysis in critically ill patients 74 . The side-effects of prolonged intravenous infusions of these and other NMBAs are yet to be fully understood and some authorities consider longterm use of these drugs still to be experimental 75 .
Prolonged neuromuscular blockade with NMBAs has been classified into two types, functional and pharmacokinetic. In the first, weakness depends on neuromuscular defects secondary to an underlying disease which may or may not be associated with NMBAs. In the second, weakness depends on prolonged drug levels which may be due to abnormal clearance, pharmacokinetics or pharmacodynamics of the NMBA drugs 76 .
A recent study demonstrated that the number of acetylcholine receptors in muscle increases after the use of NMBAs 77 . This data was suggested to explain the molecular basis for prolonged paralysis observed in critically ill patients who received these drugs. But disuse and denervation may produce the same effects 78 . Thus, denervation itself whether due to a neuropathy or to a drug blocking nerve conduction, increases the number of acetylcholine receptors. These receptors are of immature type, have reduced sensitivity to NMBAs and increased sensitivity to acetylcholine. The significance of this dysregulation in the pathophysiology of the acute weakness syndromes is not clear and needs to be further investigated 79 . Up-regulation also occurs in other receptors. For example, the cytoplasmic steroid receptor number also rises during denervation, and a threefold increase has been noted at three weeks 58 . These findings suggest that each of high endogenous blood concentrations of corticosteroids, therapeutic steroid therapy, and NMBAs of similar steroidal structure, either separately or in combination, could produce acute myopathy 80 . Other mechanisms that may play a less important role are the binding of NMBAs to basement membrane which may become a reservoir when the blood levels decrease, and channel blockade caused by some NMBAs, local anaesthetics and antibiotics 75, 81 .
Among the NMBAs, vecuronium has been described in association with dysfunction of neuromuscular transmission and also with impaired elimination 36, 77 . Vecuronium and its metabolites are not removed by haemodialysis, and accumulate in renal and liver dysfunction. Laudanosine, a metabolite of atracurium, also accumulates with renal and liver dysfunction but has not been associated with measurable central neurological effects despite its potential to do so, and despite detectable plasma concentrations in critically ill patients 76, 82, 83 . Organ dysfunction plays a significant role in reduced clearance of NMBAs, but so does age, pregnancy, obesity, acid/base and electrolyte abnormalities.
RECOMMENDATIONS FOR PATIENT MANAGEMENT
Although the precise aetiology of the weakness syndromes in critically ill patients remains unknown, many of the predisposing factors have been identified. Avoiding and reducing the exposure of patients to these following factors may help to decrease the incidence and severity of these syndromes.
Corticosteroids
The lowest dose of corticosteroid known to be effective for the primary disease should be used, and rapid weaning should be commenced as soon as possible-preferably commencing after the first 48 hours. High total doses of corticosteroid have been associated with myopathy, especially in patients who had received more than 5 grams of hydrocortisone. In patients with acute severe asthma, initial doses of hydrocortisone 100-200 mg IV 6 hourly are adequate and should be decreased to 100 mg IV 6 hourly as soon as possible. Higher doses are not more effective, and may have increased side-effects. Early introduction of inhaled corticosteroids may assist more rapid reduction in the dose of intravenous corticosteroid required. Budesonide 1 mg nebulized twice a day is recommended.
Neuromuscular Blocking Agents (NMBAs)
When NMBAs are required, intermittent bolus doses are preferred because infusions are associated with higher total NMBA dosages, and more complete muscle inactivity than bolus dosing. NMBA infusions will however be essential in some patients and infusions should then be ceased within 24 hours whenever possible. In patients with acute asthma, weaning should first be attempted in all patients within 48 hours. Avoiding vecuronium alone is not the solution, because atracurium has also been found to be associated with weakness in patients with asthma when used in addition to corticosteroids 34, 84 . NMBAs of all types potentiate the effects of steroids on muscle by increasing the number of steroid receptors. However atracurium may be logically preferred in patients with liver or kidney dysfunction to avoid the retention of long-acting vecuronium metabolites. Atracurium has non-organ-dependent metabolic pathways (Hofmann elimination and ester hydrolysis). In these patients, therapeutic use of either pancuronium or vecuronium will always be complicated by unpredictably prolonged activity of the NMBA or of its metabolites. There may be some patients in whom heavy sedation (perhaps assisted by propofol or by inhalational anaesthetics for short periods) may avoid the need for NMBAs altogether. The addition of an NMBA to corticosteroids increases the risk of acute weakness syndromes from nil (corticosteroids alone) to 26% (corticosteroids plus NMBA) 84 .
To avoid overdosage, neuromuscular monitoring should be mandatory in all critically ill patients receiving NMBAs. When intermittent doses are used the recommended technique is a train of four (TOF), but when continuous and prolonged infusions are used instead the post-tetanic count stimulation (PTC) is preferred 85 . NMBA infusions should be ceased twice daily, allowing the NMBA to wear off and allowing assessment of muscle recovery using TOF. Two to three responses are an adequate target if paralysis is still required. However regular cessation of NMBA infusions does not unfortunately guarantee protection from weakness 16 and serial measurements of CPK are still indicated to allow early detection of muscle damage.
Some authors have suggested the daily use of neostigmine, edrophonium, or pyridostigmine in quadriparetic patients after the prolonged use of NMBAs 86 to test reversibility. However there is no data available concerning efficacy of reversant drugs in these patients, and recognized side-effects suggest that prolonged use of these drugs to be unwise 95 . Neostigmine down-regulates acetylcholine receptors by allowing accumulation of acetylcholine at the neuromuscular junction 75 .
Beta-Adrenergic Agonists
In patients with asthma, beta 2 agonists should be infused intravenously at the lowest effective doses. Practically this means infusing intravenous salbutamol wherever possible at rates of less than 10 micro-grams/min. Higher rates have a higher incidence of lactic acidosis which resolves on dose reduction. Blood lactate and bicarbonate levels should be repeatedly monitored and blood concentrations of CPK and CPK-MB should be measured daily.
Metabolic and Other Factors
Fever should be actively treated as it can trigger myopathy and rhabdomyolysis, and has also been suggested as a cause of some cases of CIP 72 . Hyperosmolar states hypoalbuminaemia, hyperglycaemia, hypophosphataemia, hypokalaemia and hypermagnesemia should all also be identified and treated without delay.
Other possibly important factors include hypercapnic acidosis which is usually unavoidable in mechanically ventilated patients with asthma, and lactic acidosis which can be minimized in patients with asthma by dose reduction of intravenous salbutamol and adrenaline.
CONCLUSIONS
In recent years it has become clear that both the frequency and severity of weakness syndromes in critically ill patients has been underestimated, and the magnitude of the problem is at present unknown. Weakness syndromes in critically ill patients are multifactorial. Important contributors include the patients neuromuscular status before admission to intensive care drugs-particularly including corticosteroids and NMBAs of all types, cytokines, and the degree of coincident disuse muscle atrophy. Less important contributors include aminoglycoside antibiotics, beta 2 agonists and metabolic factors including acidosis, hyperosmolar states, hypoalbuminaemia, severe hypokalaemia, hypophosphataemia and tissue hypoxia.
Both neuropathy and myopathy can coexist, as they do in some patients with severe asthma, and neuropathy or myopathy can be aggravated by the other. Guillain-Barré syndrome may develop in some patients following admission to ICU or may in retrospect be the real reason for admission to ICU. Guillain-Barré syndrome can be very difficult to differentiate from other neuropathies, particularly CIP (Table 3 47 ).
The terms "critical illness polyneuropathy" 87 and "acute necrotizing myopathy" 32 are the two most appropriate to describe the two primary acute weakness syndromes presently recognised in critically ill patients. The first comprises those patients with diagnostic features of axonal polyneuropathy, and the second those patients with predominant muscle involvement. Present literature suggests these syndromes are separate and distinct entities. Each may however coexist with the other and the combination may then be termed polyneuromyopathy (Figure 1 ). In this context it is usually impossible to determine which entity was primarily responsible for the clinical findings.
There is a pressing need for more precise data acquisition than has occurred to date in critically ill patients with acute severe weakness syndromes. Each critically ill patient with acute neuromuscular failure should be carefully evaluated. Essential diagnostic tests include serial blood CPK and CK-MB concentrations, EMG and nerve conduction studies by experienced operators, and muscle biopsy. Recent electrophysiological techniques may further clarify the diagnosis 88 . Nuclear magnetic resonance may in future prove useful as a research tool 89 .
Larger, prospective studies are required to facilitate a better understanding of the acute severe weakness syndromes in critically ill patients and use of consistent nomenclature (Table 1) will be an essential part of the design and reporting of these studies. In the meanwhile avoidance and minimization of precipitants remains the best prophylactic measure.
